Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.36
AMAG's Cash to Debt is ranked higher than
66% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. AMAG: 2.36 )
AMAG' s 10-Year Cash to Debt Range
Min: 2.36   Max: No Debt
Current: 2.36

Equity to Asset 0.43
AMAG's Equity to Asset is ranked higher than
59% of the 772 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. AMAG: 0.43 )
AMAG' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.98
Current: 0.43

0.34
0.98
Interest Coverage No Debt
AMAG's Interest Coverage is ranked higher than
72% of the 447 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMAG: No Debt )
AMAG' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 1.41
M-Score: -3.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -10.28
AMAG's Operating margin (%) is ranked higher than
78% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. AMAG: -10.28 )
AMAG' s 10-Year Operating margin (%) Range
Min: -18217.46   Max: 8.03
Current: -10.28

-18217.46
8.03
Net-margin (%) -13.99
AMAG's Net-margin (%) is ranked higher than
77% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. AMAG: -13.99 )
AMAG' s 10-Year Net-margin (%) Range
Min: -15420.63   Max: 31.64
Current: -13.99

-15420.63
31.64
ROE (%) -6.90
AMAG's ROE (%) is ranked higher than
79% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. AMAG: -6.90 )
AMAG' s 10-Year ROE (%) Range
Min: -86.79   Max: 5.49
Current: -6.9

-86.79
5.49
ROA (%) -3.69
AMAG's ROA (%) is ranked higher than
80% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. AMAG: -3.69 )
AMAG' s 10-Year ROA (%) Range
Min: -67.05   Max: 3.34
Current: -3.69

-67.05
3.34
ROC (Joel Greenblatt) (%) -422.53
AMAG's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. AMAG: -422.53 )
AMAG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1009.91   Max: 12.16
Current: -422.53

-1009.91
12.16
Revenue Growth (%) 5.50
AMAG's Revenue Growth (%) is ranked higher than
80% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. AMAG: 5.50 )
AMAG' s 10-Year Revenue Growth (%) Range
Min: -31.2   Max: 265.9
Current: 5.5

-31.2
265.9
EBITDA Growth (%) -53.50
AMAG's EBITDA Growth (%) is ranked higher than
54% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. AMAG: -53.50 )
AMAG' s 10-Year EBITDA Growth (%) Range
Min: -74.5   Max: 320.8
Current: -53.5

-74.5
320.8
EPS Growth (%) -51.70
AMAG's EPS Growth (%) is ranked higher than
56% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. AMAG: -51.70 )
AMAG' s 10-Year EPS Growth (%) Range
Min: -51.7   Max: 78.1
Current: -51.7

-51.7
78.1
» AMAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AMAG Guru Trades in Q3 2013

Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q4 2013

AMAG Guru Trades in Q4 2013

Jim Simons 40,176 sh (New)
Paul Tudor Jones 15,600 sh (New)
Steven Cohen 11,244 sh (New)
» More
Q1 2014

AMAG Guru Trades in Q1 2014

Jim Simons 125,160 sh (+211.53%)
Paul Tudor Jones 22,400 sh (+43.59%)
Steven Cohen Sold Out
» More
Q2 2014

AMAG Guru Trades in Q2 2014

Jim Simons 129,060 sh (+3.12%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.78
AMAG's P/B is ranked higher than
73% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. AMAG: 3.78 )
AMAG' s 10-Year P/B Range
Min: 1.12   Max: 18.97
Current: 3.78

1.12
18.97
P/S 8.18
AMAG's P/S is ranked higher than
77% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. AMAG: 8.18 )
AMAG' s 10-Year P/S Range
Min: 3.62   Max: 406.82
Current: 8.18

3.62
406.82
EV-to-EBIT -55.60
AMAG's EV-to-EBIT is ranked higher than
75% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMAG: -55.60 )
AMAG' s 10-Year EV-to-EBIT Range
Min: -55.5   Max: -0.2
Current: -55.6

-55.5
-0.2
Current Ratio 11.40
AMAG's Current Ratio is ranked higher than
91% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. AMAG: 11.40 )
AMAG' s 10-Year Current Ratio Range
Min: 3.27   Max: 54.4
Current: 11.4

3.27
54.4
Quick Ratio 10.81
AMAG's Quick Ratio is ranked higher than
91% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. AMAG: 10.81 )
AMAG' s 10-Year Quick Ratio Range
Min: 3.02   Max: 54.33
Current: 10.81

3.02
54.33

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.59
AMAG's Price/Net Cash is ranked higher than
91% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 125.18 vs. AMAG: 5.59 )
AMAG' s 10-Year Price/Net Cash Range
Min: 1   Max: 147.92
Current: 5.59

1
147.92
Price/Net Current Asset Value 4.88
AMAG's Price/Net Current Asset Value is ranked higher than
90% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 57.00 vs. AMAG: 4.88 )
AMAG' s 10-Year Price/Net Current Asset Value Range
Min: 0.97   Max: 80.68
Current: 4.88

0.97
80.68
Price/Tangible Book 4.15
AMAG's Price/Tangible Book is ranked higher than
83% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.79 vs. AMAG: 4.15 )
AMAG' s 10-Year Price/Tangible Book Range
Min: 0.78   Max: 11.36
Current: 4.15

0.78
11.36
Price/Median PS Value 0.32
AMAG's Price/Median PS Value is ranked higher than
97% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. AMAG: 0.32 )
AMAG' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 66.5
Current: 0.32

0.13
66.5
Earnings Yield (Greenblatt) -1.80
AMAG's Earnings Yield (Greenblatt) is ranked lower than
187% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AMAG: -1.80 )
AMAG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -1.8

Forward Rate of Return (Yacktman) -58.07
AMAG's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. AMAG: -58.07 )
AMAG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -65.2   Max: 80
Current: -58.07

-65.2
80

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AMU.Germany
AMAG Pharmaceuticals, Inc., a Delaware corporation was founded in 1981. The Company is a specialty pharmaceutical company focused on the development and commercialization of Feraheme (ferumoxytol) Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA. Its main source of revenue is from the sale of Feraheme, which was approved for marketing in the U.S. in June 2009 by the U.S. Food and Drug Administration, or the FDA, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease, or CKD. The Company sells Feraheme to authorized wholesalers and specialty distributors, who in turn, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers, and nephrology clinics.The Company's core technology is based on coated superparamagnetic iron oxide particles and their characteristic properties. The development, manufacture and commercialization of pharmaceutical products are subject to extensive regulation by numerous governmental authorities in the U.S. and abroad. In the U.S., the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations govern, among other things, the research and development, manufacturing, quality control (testing), labeling, record-keeping, approval, storage, distribution, and advertising and promotion of pharmaceutical products.
» More Articles for AMAG

Headlines

Articles On GuruFocus.com
AMAG Pharmaceuticals Inc. (AMAG) EVP, CFO David Arkowitz sells 2,705 Shares Feb 28 2011 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 230,011 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. (AMAG) CFO and Chief Business Officer David Arkowitz sells 4,459 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2009 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 5,000 Shares Aug 05 2009 

More From Other Websites
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure Oct 21 2014
Should You Buy AMAG Pharmaceuticals (AMAG) Ahead of Earnings? Oct 20 2014
Can the Rally in AMAG Pharmaceuticals (AMAG) Shares Continue? Oct 02 2014
AMAG Up on Roughly $1B deal with Lumara to Widen Portfolio Sep 30 2014
AMAG Pharma upgraded by FBR Capital Sep 30 2014
Athlon and DreamWorks are big market movers Sep 29 2014
Amag Pharma enters women health business with $675 mln deal Sep 29 2014
Why AMAG Pharmaceuticals (AMAG) Stock Is Up Today Sep 29 2014
Amag, Perrigo Buy Lumara in Two-Step Deal Valued at $1.1B Sep 29 2014
Morning Movers: Athlon Soars on Encana Buyout; DreamWorks Jumps on Softbank Chatter Sep 29 2014
Lumara Health to sell assets to AMAG, Perrigo for $757 million Sep 29 2014
[$$] Lumara Health to Sell Assets Sep 29 2014
Amag Pharma buys women's health company Lumara for $675 mln Sep 29 2014
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Sep 29 2014
Lumara Health™ to be Acquired in Two Separate Transactions for up to $1.107 Billion Sep 29 2014
AMAG Pharmaceuticals to Acquire Lumara Health Maternal Health Business Sep 29 2014
AMAG Pharmaceuticals Appoints Judith Johnson, M.D. as Vice President of Pharmacovigilance and... Sep 16 2014
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 12 2014
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Sep 08 2014
AMAG Pharmaceuticals Announces Appointment of John A. Fallon, M.D. to Board of Directors Sep 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK